About This Event
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biotech company, visits the Nasdaq MarketSite in Times Square. Cullinan will celebrate the 5th anniversary of its initial public offering and set the stage for 2026, a defining year for the company, where Cullinan plans to deliver multiple catalysts for its two high-priority T cell engager programs, CLN-978 and CLN-049. In immunology, we are developing CLN-978, a potential best-in-class CD19xCD3 T cell engager for patients with rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s disease. In oncology, we are excited about CLN-049, a potential first-in-class FLT3xCD3 T cell engager in development for acute myeloid leukemia.
In honor of the occasion, Nadim Ahmed, President and Chief Executive Officer rings the Opening Bell.
